{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:01:34Z","timestamp":1793314894572,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002738","name":"Assistance Publique - Hopitaux de Paris","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.coi.2025.102628","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T06:53:53Z","timestamp":1754463233000},"page":"102628","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Complement in antiphospholipid syndrome, time to target?"],"prefix":"10.1016","volume":"96","author":[{"given":"Marie-Agn\u00e8s","family":"Dragon Durey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houcine","family":"Hamidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Darnige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102628_bib1","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/bmj.287.6399.1088","article-title":"Thrombosis, abortion, cerebral disease, and the lupus anticoagulant","volume":"287","author":"Hughes","year":"1983","journal-title":"Br Med J (Clin Res Ed)"},{"key":"10.1016\/j.coi.2025.102628_bib2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome registry project group: catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"Asherson","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2025.102628_bib3","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1024\/0301-1526\/a000723","article-title":"Antiphospholipid syndrome \u2014 an update","volume":"47","author":"Linnemann","year":"2018","journal-title":"Vasa"},{"key":"10.1016\/j.coi.2025.102628_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1006\/jaut.2000.0409","article-title":"Epidemiology of the antiphospholipid antibody syndrome","volume":"15","author":"Petri","year":"2000","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102628_bib5","doi-asserted-by":"crossref","first-page":"10794","DOI":"10.1074\/jbc.RA120.013939","article-title":"The J-elongated conformation of \u03b22-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome","volume":"295","author":"Ruben","year":"2020","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coi.2025.102628_bib6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102628_sbref7","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jtha.2022.12.002","article-title":"Targeting thromboinflammation in antiphospholipid syndrome","volume":"21","author":"Salet","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2025.102628_bib8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.thromres.2016.09.004","article-title":"Inverted erythrocyte membranes demonstrate \u03b22GPI-antiphospholipid antibody interactions and membrane crosslinking","volume":"146","author":"Bloemen","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.coi.2025.102628_sbref9","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350832","article-title":"Autoantibodies against complement proteins in patients with antiphospholipid syndrome: prevalence and clinical associations","volume":"54","author":"Philip","year":"2024","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coi.2025.102628_bib10","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/09612033251322927","article-title":"Risk factors for bleeding in patients with thrombotic antiphospholipid syndrome during antithrombotic therapy","volume":"34","author":"Gaspar","year":"2025","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2025.102628_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I \u2014 molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102628_bib12","first-page":"886","article-title":"C1 inhibitor, a multi-functional serine protease inhibitor","volume":"104","author":"Iii","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2025.102628_bib13","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.jtha.2023.03.024","article-title":"High plasma levels of C1-inhibitor are associated with lower risk of future venous thromboembolism","volume":"21","author":"Grover","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2025.102628_bib14","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1038\/s44318-024-00128-y","article-title":"Higher-order structure and proteoforms of co-occurring C4b-binding protein assemblies in human serum","volume":"43","author":"Kadav\u00e1","year":"2024","journal-title":"EMBO J"},{"key":"10.1016\/j.coi.2025.102628_bib15","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1182\/blood-2011-02-339564","article-title":"\u03b2\u2082-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator","volume":"118","author":"Gropp","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102628_bib16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jtha.2024.01.006","article-title":"Thrombomodulin: a multifunctional receptor modulating the endothelial quiescence","volume":"22","author":"Giri","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.coi.2025.102628_bib17","first-page":"3006","article-title":"The elusive physiologic role of Factor XII","volume":"118","author":"Schmaier","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2025.102628_bib18","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1161\/01.CIR.94.7.1746","article-title":"Thrombogenic properties of murine anti-cardiolipin antibodies induced by beta 2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies","volume":"94","author":"Pierangeli","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.coi.2025.102628_bib19","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1196\/annals.1422.058","article-title":"C5a receptor-deficient mice are protected from thrombophilia and endothelial cell activation induced by some antiphospholipid antibodies","volume":"1108","author":"Romay-Penabad","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.coi.2025.102628_bib20","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1191\/0961203303lu405oa","article-title":"The effects of antiphospholipid antibodies obtained from women with SLE\/APS and associated pregnancy loss on rat embryos and placental explants in culture","volume":"12","author":"Ornoy","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2025.102628_bib21","first-page":"455","article-title":"Antiphospholipid antibodies and complement activation in patients with cerebral ischemia","volume":"10","author":"Davis","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2025.102628_bib22","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1136\/ard.2008.090670","article-title":"Complement activation in patients with primary antiphospholipid syndrome","volume":"68","author":"Oku","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102628_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9060671","article-title":"Low preconception complement levels are associated with adverse pregnancy outcomes in a multicenter study of 260 pregnancies in 197 women with antiphospholipid syndrome or carriers of antiphospholipid antibodies","volume":"9","author":"Nalli","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.coi.2025.102628_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.957201","article-title":"Circulating immune-complexes of IgG\/IgM bound to B2-glycoprotein-I associated with complement consumption and thrombocytopenia in antiphospholipid syndrome","volume":"13","author":"Naranjo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102628_sbref25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2024.105760","article-title":"Cluster analysis of clinical manifestations assigns systemic lupus erythematosus-phenotype subgroups: a multicentre study on 440 patients","volume":"91","author":"Mariette","year":"2024","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.coi.2025.102628_bib26","first-page":"2088","article-title":"High plasma C5a and C5b-9 levels during quiescent phases are associated to severe antiphospholipid syndrome subsets","volume":"40","author":"Ruffatti","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2025.102628_sbref27","first-page":"1875","article-title":"Relevance of inflammatory and complement activation biomarkers profiling in antiphospholipid syndrome patients outside acute thrombosis","volume":"41","author":"Yelnik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.coi.2025.102628_sbref28","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/rheumatology\/kead517","article-title":"Antiphospholipid antibody carriers and patients with quiescent antiphospholipid syndrome show persistent subclinical complement activation","volume":"63","author":"Zen","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102628_bib29","doi-asserted-by":"crossref","first-page":"4248","DOI":"10.1182\/blood.V93.12.4248","article-title":"Some anticardiolipin antibodies recognize a combination of phospholipids with thrombin-modified antithrombin, complement C4b-binding protein, and lipopolysaccharide binding protein","volume":"93","author":"Arvieux","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102628_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2025.107002","article-title":"Autoantibodies and therapeutic antibodies against complement factor H","volume":"274","author":"Nugteren","year":"2025","journal-title":"Immunol Lett"},{"key":"10.1016\/j.coi.2025.102628_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00773","article-title":"Blood cell-bound C4d as a marker of complement activation in patients with the antiphospholipid syndrome","volume":"10","author":"Lonati","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102628_sbref32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1459842","article-title":"Cell-bound complement activation products in antiphospholipid antibody-positive patients without other systemic autoimmune rheumatic diseases","volume":"15","author":"Erkan","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102628_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","article-title":"Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS","volume":"135","author":"Chaturvedi","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102628_bib34","article-title":"Genetic and epigenetic dysregulation of CR1 is associated with catastrophic antiphospholipid syndrome (CAPS)","author":"Ranjan","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.coi.2025.102628_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060352","article-title":"Determining the population frequency of the CFHR3\/CFHR1 deletion at 1q32","volume":"8","author":"Holmes","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2025.102628_bib36","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa0810739","article-title":"Thrombomodulin mutations in atypical hemolytic-uremic syndrome","volume":"361","author":"Delvaeye","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102628_bib37","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.autrev.2015.01.008","article-title":"Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature","volume":"14","author":"Viall","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2025.102628_bib38","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1177\/1093526619836025","article-title":"Absence of distinct immunohistochemical distribution of Annexin A5, C3b, C4d, and C5b-9 in placentas from patients with antiphospholipid antibodies, preeclampsia, and systemic lupus erythematosus","volume":"22","author":"Matrai","year":"2019","journal-title":"Pediatr Dev Pathol"},{"key":"10.1016\/j.coi.2025.102628_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13185","article-title":"Complement activation in the plasma and placentas of women with different subsets of antiphospholipid syndrome","volume":"82","author":"Scambi","year":"2019","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.coi.2025.102628_bib40","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3899\/jrheum.2022-1200","article-title":"Efforts to better characterize \u201cantiphospholipid antibody nephropathy\u201d for the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria: renal pathology subcommittee report","volume":"51","author":"Barbhaiya","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2025.102628_bib41","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00296-018-4040-2","article-title":"Renal involvement in antiphospholipid syndrome","volume":"38","author":"de Azevedo","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.coi.2025.102628_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102889","article-title":"Renal and vascular outcomes in patients with isolated antiphospholipid syndrome nephropathy","volume":"132","author":"Rousselin","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102628_sbref43","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1093\/rheumatology\/keae397","article-title":"Kidney whole-transcriptome profiling in primary antiphospholipid syndrome reveals complement, interferons and NETs-related gene expression","volume":"63","author":"Tektonidou","year":"2024","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102628_sbref44","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","article-title":"The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"106","author":"Vivarelli","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.coi.2025.102628_bib45","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1177\/096120339600500306","article-title":"Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves","volume":"5","author":"Ziporen","year":"1996","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2025.102628_bib46","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood-2015-09-672139","article-title":"Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery","volume":"127","author":"Meroni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102628_bib47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.coi.2025.102628_bib48","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102628_bib49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/10892532241249782","article-title":"Management of anticoagulation and antifibrinolytics in catastrophic antiphospholipid syndrome","volume":"28","author":"Park","year":"2024","journal-title":"Semin Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.coi.2025.102628_bib50","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102628_bib51","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/ajt.12319","article-title":"Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes","volume":"13","author":"Canaud","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.coi.2025.102628_bib52","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102628_bib53","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.2020007499","article-title":"Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab","volume":"136","author":"Yelnik","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102628_sbref54","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","article-title":"Complement in human disease: approved and up-and-coming therapeutics","volume":"403","author":"West","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102628_bib55","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1160\/TH11-08-0554","article-title":"Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome","volume":"107","author":"Breen","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.coi.2025.102628_bib56","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2023-182287","article-title":"Complement activation is increased in antiphospholipid syndrome-related ischemic stroke with higher risk features","volume":"142","author":"Tohidi-Esfahani","year":"2023","journal-title":"Blood"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:10:59Z","timestamp":1762337459000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525001049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":56,"alternative-id":["S0952791525001049"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102628","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complement in antiphospholipid syndrome, time to target?","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102628","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102628"}}